Loading…
Evidence-based medicine, made clear. Each week, The Medical Brief breaks down important studies, emerging treatments, diseases, and the science shaping modern healthcare. Clear context, careful explanations, and no sensationalism. For educational purposes only, not medical advice. Brought to you by Jellypod.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
36%
Guest openness
Selective
Sign up to generate a grounded pitch for The Medical Brief.
Signup to Generate a PitchThe Medical Brief is a general podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
Unknown Host hosts The Medical Brief, a general show with 0 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #22
<p>A critical care discussion of why sodium bicarbonate often looks helpful on the blood gas but fails to improve outcomes in vasopressor-dependent metabolic acidosis. The episode breaks down the SODa BIC trial, the surrogate endpoint trap, and when bicarbonate may still have a role in select ICU patients.</p>
Episode #21
<p>We break down the EVERDAC trial, a multicenter randomized study asking whether critically ill patients with shock really need an immediate arterial line. The episode covers noninferior mortality outcomes, major reductions in catheter-related bleeding, and how this could shift ICU practice toward a more selective, noninvasive approach.</p><p>Show Notes</p>Deferring Arterial Catheterization in Critically Ill Patients with Shock | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2502136
Episode #20
<p>This episode examines the EARLY TAVR trial and why “asymptomatic” severe aortic stenosis may be misleading, with treadmill testing revealing many patients were not truly symptom-free. It also breaks down the results: fewer unplanned hospitalizations with early intervention, but no clear mortality benefit yet, alongside the procedural risks and shared decision-making implications.</p>
Episode #19
<p>A deep dive into the CLL17 trial and the shift from indefinite BTK inhibition to fixed-duration venetoclax-based therapy. The hosts unpack noninferior progression-free survival, striking MRD clearance, and the trade-offs between continuous treatment and a defined endpoint.</p><p>Show Notes</p>Fixed-Duration versus Continuous Treatment for Chronic ...: https://www.nejm.org/doi/full/10.1056/NEJMoa2515458
Episode #18
<p>This episode breaks down the APPLAUSE IgAN phase 3 trial of iptacopan in high-risk IgA nephropathy, highlighting meaningful slowing of eGFR decline, lower kidney failure events, and how surrogate proteinuria changes translated into real clinical benefit.</p><p>It also examines the trade-off of complement blockade, including the need for careful vaccination and the increased risk of serious infections in patients with severe proteinuria.</p><p>Show Notes</p>Iptacopan Slows Kidney Function Decline in IgA Nephropathy: https://www.renalandurologynews.com/news/iga-neprhopathy-iptacopan-kidney-function-treatment-risk/Iptacopan for IgA Nephropathy in: https://www.kidneynews.org/view/journals/kidney-news/18/5/article-p29_19.xml
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
